SBFM - Sunshine Biopharma Inc

Momentum: Bearish

Recent News

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug - Sunshine Biopharma ( NASDAQ:SBFM )

Benzinga • 5 months, 1 week ago • score: 0.09

Sunshine Biopharma's K1.1 mRNA-LNP reduced human HCC tumor growth in mice with good tolerability under repeated dosing. The company's 2024 revenue rose 45% year over year to $34.9 million. The 'Trade of the Day' is now live. Get a high-probability setup with clear entry and exit points right here.

Neutral

NORA PHARMA RECEIVES HEALTH CANADA APPROVAL FOR NIOPEG®, A BIOSIMILAR OF NEULASTA®

Canada Newswire • 1 year, 4 months ago • score: 0.03

VARENNES, QC, April 19, 2024 /CNW/ - Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® ( a pegylated form ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the development of anticancer drugs. The company is headquartered in Pointe-Claire, Canada.

52W High

$3.75

52W Low

$1.17

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.40

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-7.73

EV/Revenue (<3 favorable)

0.01

P/S (TTM) (<3 favorable)

0.17

P/B (<3 favorable)

0.24

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

3.17%

Institutions (25–75% balanced)

2.85%

Shares Outstanding

4,555,900

Float

4,553,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

36,341,700

Gross Profit (TTM)

12,112,500

EPS (TTM)

-15.02

Profit Margin (>10% good)

-0.17%

Operating Margin (TTM) (higher better)

-0.11%

ROE (TTM) (>15% strong)

-0.26%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.01

Momentum

Bearish momentum

Value

-0.0020

-0.0095

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025